TY - JOUR
T1 - The association of previous influenza vaccination and coronavirus disease-2019
AU - Green, Ilan
AU - Ashkenazi, Shai
AU - Merzon, Eugene
AU - Vinker, Shlomo
AU - Golan-Cohen, Avivit
N1 - Publisher Copyright:
© 2020 Leumit Health Services.
PY - 2021
Y1 - 2021
N2 - Studies have shown similarities in the structure of influenza and coronaviruses, in their binding receptors and in patterns of immune responses; and that influenza vaccine can induce cross-immunity. We examined the association of previous influenza vaccination and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, resulting in coronavirus disease-2019 (COVID-19), among 715,164 members of a health maintenance organization. In a multivariate regression model, the odds ratios for SARS-CoV-2 infection among individuals vaccinated for influenza in 2018–2019, 2019–2020, and in both seasons, compared to non-vaccinated individuals, were 0.82 (95% CI 0.68–0.99, p = .048), 0.79 (95% CI 0.67–0.98, p = .005), and 0.76 (95% CI 0.61–0.97, p = .004), respectively. Based on our findings, administration of influenza vaccine before the influenza season is highly recommended to reduce the burden of influenza, which is critical in scenarios of outbreaks of both influenza and SARS-CoV-2 infections, and also regarding its association with reduced rate of COVID-19.
AB - Studies have shown similarities in the structure of influenza and coronaviruses, in their binding receptors and in patterns of immune responses; and that influenza vaccine can induce cross-immunity. We examined the association of previous influenza vaccination and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, resulting in coronavirus disease-2019 (COVID-19), among 715,164 members of a health maintenance organization. In a multivariate regression model, the odds ratios for SARS-CoV-2 infection among individuals vaccinated for influenza in 2018–2019, 2019–2020, and in both seasons, compared to non-vaccinated individuals, were 0.82 (95% CI 0.68–0.99, p = .048), 0.79 (95% CI 0.67–0.98, p = .005), and 0.76 (95% CI 0.61–0.97, p = .004), respectively. Based on our findings, administration of influenza vaccine before the influenza season is highly recommended to reduce the burden of influenza, which is critical in scenarios of outbreaks of both influenza and SARS-CoV-2 infections, and also regarding its association with reduced rate of COVID-19.
KW - COVID-19
KW - coronaviruses
KW - cross-protection
KW - immunization
KW - influenza vaccine
KW - sars-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85098552654&partnerID=8YFLogxK
U2 - 10.1080/21645515.2020.1852010
DO - 10.1080/21645515.2020.1852010
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 33377817
AN - SCOPUS:85098552654
SN - 2164-5515
VL - 17
SP - 2169
EP - 2175
JO - Human Vaccines and Immunotherapeutics
JF - Human Vaccines and Immunotherapeutics
IS - 7
ER -